Company: ABBV
Filing Date: 2025-03-24
Form Type: DEF 14A
Source: 0001558370-25-003537
Chunk: 91

Company: AbbVie Inc.
Filing Date: 2025-03-24
Form: DEF 14A
Chunk 91
---
 for Approval of Related Person Transactions It is AbbVie’s policy that the nominations and governance committee conduct a reasonable prior review and approve or disapprove of all transactions in which AbbVie participates and in which any related person has a direct or indirect material interest if such transaction involves or is expected to involve payments of $120,000 or more in the aggregate per fiscal year. Related person transactions requiring review by the nominations and governance committee pursuant to this policy are identified in:

| ● | questionnaires annually distributed to AbbVie’s directors and executive officers; |

| ● | certifications submitted annually by AbbVie executive officers related to their compliance with AbbVie’s Code of Business Conduct; or |

| ● | communications made directly by the related person to the chief financial officer or general counsel. |

In determining whether to approve or disapprove a related person transaction, the nominations and governance committee will consider the following items, among others:

| ● | the related person’s relationship to AbbVie and interest in the transaction; |

| ● | the material facts of the transaction, including the aggregate value of such transaction or, in the case of indebtedness, the amount of principal involved; |

| ● | the benefits to AbbVie of the transaction; |

| ● | if applicable, the availability of other sources of comparable products or services; |

| ● | an assessment of whether the transaction is on terms that are comparable to the terms available to an unrelated third party or to employees generally; |

| ● | whether a transaction has the potential to impair director independence; and |

| ● | whether the transaction constitutes a conflict of interest. |

This process is included in the nominations and governance committee’s written charter, which is available on the governance section of AbbVie’s investor relations website at www.abbvieinvestor.com. Nicholas Donoghoe, M.D., Executive Vice President, Chief Business and Strategy Officer, was appointed as an executive officer of AbbVie during 2023. Dr. Donoghoe’s wife, Jessica Heckmann Donoghoe, is a minority equity owner in LaserAway, a chain of aesthetics clinics. Dr. Donoghoe’s brothers-in-law Brock Heckmann, Scott Heckmann, and Todd Heckmann are also equity owners, as well as executives, at LaserAway. LaserAway purchased $12.6 million worth of AbbVie products during 2024, including Botox Cosmetic, Juvederm, and Coolsculpting. LaserAway also receives product samples for educational and other training